The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results.
 
Daron G. Street
No Relationships to Disclose
 
Luke Kuttschreuter
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Expert Testimony - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
David Starks
No Relationships to Disclose
 
Haider Mahdi
Research Funding - ALX Oncology (Inst); Citius Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Merck (Inst)
 
Carlos Linn
Employment - Pfizer
Stock and Other Ownership Interests - Eli Lilly Co; Pfizer
 
Dmitri Pavlov
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen
Consulting or Advisory Role - Exigent Research Network
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Ingmar Bruns
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Steven E. Waggoner
Research Funding - Genentech (Inst); Trillium Therapeutics (Inst)